Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Revenue

Cartesian Therapeutics had revenue of $78.00K in the quarter ending March 31, 2026, a decrease of -92.91%. This brings the company's revenue in the last twelve months to $1.78M, down -94.81% year-over-year. In the year 2025, Cartesian Therapeutics had annual revenue of $2.80M, down -92.81%.

• Revenue (ttm): $1.78M
• Revenue Growth: -94.81%
• P/S Ratio: 116.86
• Revenue / Employee: $23,667
• Employees: 75
• Market Cap: 212.43M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.80M	-36.12M	-92.81%
Dec 31, 2024	38.91M	12.91M	49.64%
Dec 31, 2023	26.00M	-84.77M	-76.53%
Dec 31, 2022	110.78M	25.70M	30.21%
Dec 31, 2021	85.08M	68.48M	412.60%
Dec 31, 2020	16.60M	9.92M	148.57%
Dec 31, 2019	6.68M	5.77M	639.42%
Dec 31, 2018	903.00K	696.00K	336.23%
Dec 31, 2017	207.00K	-7.88M	-97.44%
Dec 31, 2016	8.08M	2.07M	34.47%
Dec 31, 2015	6.01M	2.97M	97.73%
Dec 31, 2014	3.04M	1.56M	105.54%
Dec 31, 2013	1.48M	-	-

Data Source: Fiscal.ai Last updated: Apr 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 27, 2026

Data Sources Report a data error